About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Lenalidomide Monotherapy in R/R DLBCL | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT04150328

Lenalidomide Monotherapy in R/R DLBCL

This observational study is designed to characterise the effectiveness of lenalidomide monotherapy in the treatment of R/R DLBCL and to compare the results with the efficacy outcomes of a tafasitamab-...

Lead sponsor: MorphoSys AG•8 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Sponsors

Lead Sponsor

MorphoSys AG

Tafasitamab (MOR00208) is currently in development for the treatment of R/R DLBCL. An ongoing, single-arm, phase II, open label, multicenter study (MOR208C203) is evaluating the efficacy and safety of tafasitamab combined with lenalidomide in patients with R/R DLBCL. In order to establish a lenalidomide monotherapy as a control cohort, this observational study aims to collect retrospective lenalidomide monotherapy data from real-world-evidence and to compare it with the tafasitamab-lenalidomide combination therapy.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Histologically confirmed diagnosis of DLBCL
•Relapsed/refractory to at least one previous systemic therapy for DLBCL
•Received at least one, but no more than three previous systemic regimens for the treatment of DLBCL, including at least one anti-CD20 containing therapy

Exclusion Criteria

•CNS involvement by lymphoma
•Patients who received lenalidomide in combination with another anti-lymphoma therapy (including radiation)
•Previously treated with anti-CD19-targeted therapy or immunomodulatory drugs
•Patients who previously underwent allogeneic SCT
•Known simultaneous detection of MYC and BCL2 or BCL6 translocation according to FISH
•Patients with a history of other malignancies within 5 years prior to lenalidomide treatment start

Related studies

RECRUITINGPhase 1

KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT07260812 · Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)

RECRUITINGPhase 1/2

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716 · B-cell Malignancy, Marginal Zone Lymphoma, and more

RECRUITINGPhase 1

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

NCT06026319 · Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, and more

RECRUITINGPhase 1

Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT07368270 · Diffuse Large B Cell Lymphoma

RECRUITINGPhase 2

DALY II Japan/MB-CART2019.1 for DLBCL

NCT07288879 · DLBCL - Diffuse Large B Cell Lymphoma, CAR T Cell Therapy

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 24, 2022Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment490

Start dateApr 2019

Last updatedAug 24, 2022

Condition

Diffuse Large B Cell Lymphoma

Locations shown

MorphoSys Research Site

Rochester, Minnesota

MorphoSys Research Site

St Louis, Missouri

MorphoSys Research Site

Manhasset, New York

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 24, 2022Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions